<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt -2.4pt 1pt 0in"><DIV STYLE="font-size: 0.75pt; border-top: Black 0.75pt solid; border-bottom: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION<BR>
</B></FONT><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM 8-K<BR>
<BR>
</B></FONT><B>Current Report<BR>
<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 19, 2012 (June 18, 2012)<BR>
</B>Date of Report (Date of earliest event reported)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MEDGENICS, INC.<BR>
</B>(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding: 0; font-weight: bold; text-align: center; text-indent: 0"><B>Delaware</B></TD>
    <TD STYLE="width: 32%; padding: 0; font-weight: bold; text-align: center; text-indent: 0"><B>1-35112</B></TD>
    <TD STYLE="width: 34%; padding: 0; font-weight: bold; text-align: center; text-indent: 0"><B>98-0217544</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(State or other jurisdiction of<BR>
incorporation or organization)</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Commission File Number)</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(I.R.S. Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>555 California Street, Suite 365</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Francisco, California 94104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(415) 568-2245<BR>
</B>(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not Applicable<BR>
(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 96%; padding: 0; text-indent: 0">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 0; font-weight: bold; text-indent: 0"><B>Item 1.01.</B></TD>
    <TD STYLE="width: 88%; padding: 0; font-weight: bold; text-indent: 0"><B>Entry into a Material Definitive Agreement.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0"><B>Item 3.02.</B></TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0"><B>Unregistered Sales of Equity Securities.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">On June 18, 2012, Medgenics, Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), entered into subscription agreements (the &ldquo;Subscription Agreements&rdquo;) with
certain accredited investors (the &ldquo;Investors&rdquo;) for the purchase and sale of an aggregate of 1,944,734 Units (the &ldquo;Units&rdquo;),
with each Unit consisting of one share of its common stock, par value $0.0001 per share, and a Warrant (collectively, the &ldquo;Investor
Warrants&rdquo;) to purchase 0.75 share of its common stock, for an aggregate offering price of $9,529,196.60. The purchase price
per Unit was $4.90. The purchase and sale of the Units pursuant to the Subscription Agreements were completed on June 18, 2012
(the &ldquo;Closing Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><FONT STYLE="font-size: 10pt; color: black">The
Units separated immediately upon closing, and the Investor Warrants were not separately listed for trading. The Investor Warrants
will first become exercisable on December 15, 2012, which is 180 days after the Closing Date, and will expire on June 18, 2017,
the fifth anniversary of the Closing Date. The Investor Warrants have an initial exercise price of $8.34 per full share of common
stock. The exercise price and number of shares issuable upon exercise of the Investor Warrants may be adjusted in certain circumstances,
including a stock split, stock dividend, recapitalization, reorganization, merger or consolidation, but will not be adjusted for
the issuance of common stock or securities convertible into or exercisable for common stock at a price below the then current exercise
price of the Investor Warrants. Holders of Investor Warrants will not have the right to exercise the Investor Warrants on a cashless
basis except during those periods, if any, that the Investor Warrants are exercisable and a registration statement with respect
to the resale of the common stock issuable upon exercise of the Investor Warrants is not effective. The terms of the Investor Warrants
are set forth in the Warrant Agreement, dated as of June 18, 2012, between the Company </FONT>and Corporate Stock Transfer, Inc.,
as warrant agent (the &ldquo;Warrant Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company intends to use the net proceeds
from the sale of the Units for research and development, general corporate purposes and working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Maxim Group LLC acted as placement agent
(the &ldquo;Placement Agent&rdquo;) in connection with the offering, and received a commission equal to 8% and a corporate finance
fee equal to 2% of the gross proceeds raised in the offering, or $952,920 in the aggregate. Maxim Partners LLC, an affiliate of
the Placement Agent, was also issued a Common Stock Purchase Warrant dated as of June 18, 2012 (the &ldquo;Placement Agent Warrant&rdquo;)
to purchase 194,473 shares of common stock (representing an amount equal to 10% of the shares sold as part of the Units) at an
initial exercise price of $9.17 per share (representing an exercise price equal to 110% of the exercise price of the Investor Warrants).
The Placement Agent Warrant will first become exercisable on December 18, 2012 and will expire on June 18, 2017. The exercise price
and number of shares issuable upon exercise of the Placement Agent Warrant may be adjusted in certain circumstances, including
a stock split, stock dividend, recapitalization, reorganization, merger or consolidation, but will not be adjusted for the issuance
of common stock or securities convertible into or exercisable for common stock at a price below the then current exercise price
of the Placement Agent Warrant. The Placement Agent Warrant may only be exercised on a cashless basis under the same terms and
conditions that the Investor Warrants may be exercised on a cashless basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In connection with the offer and sale of
the Units, the Company entered into a Registration Rights Agreement dated as of June 18, 2012 with the Investors (the &ldquo;Registration
Rights Agreement&rdquo;). Under the Registration Rights Agreement, the Company agreed to file a registration statement registering
the resale of the shares included in the Units and upon exercise of the Warrants within 30 days after the Closing Date. If the
registration statement is not filed within such 30-day period, or if the registration statement is not declared effective within
120 days after the Closing Date, the Company agreed to pay liquidated damages to the Investors equal to 1.0% of the aggregate purchase
price paid by each Investor per month. In no event will such liquidated damages exceed 5.0% of the aggregate purchase price paid
by the Investors. The Company is also obligated to register the resale of the shares issuable upon the exercise of the Placement
Agent Warrant under this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The offering and sale of the Units has been
conducted in reliance upon an exemption from registration provided for by Rule 506 of Regulation D and Section 4(2) of the Securities
Act of 1933 (the &ldquo;Act&rdquo;). No form of general solicitation or general advertising was used by the Company, or any representative
of the Company, in connection with the offer or sale of the Units. Each of the Investors was an accredited investor. The shares
of common stock issued as part of the Units, the Investor Warrants, the Placement Agent Warrant, and the shares of common stock
issuable upon exercise of the Investor Warrants and the Placement Agent Warrant are restricted securities, have been or will be
appropriately legended as such, and cannot be transferred unless they have been registered under the Act, or there is an exemption
from registration under applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The foregoing description of the Subscription
Agreements, Investor Warrants, Placement Agent Warrant and Registration Rights Agreement is only a summary and is qualified in
its entirety by reference to the full text of the form of Subscription Agreement, form of Warrant Certificate, Warrant Agreement,
Placement Agent Warrant and Registration Rights Agreement, each of which is filed as an exhibit hereto and incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 0; text-indent: 0; font-weight: bold"><B>Item 7.01 </B></TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; font-weight: bold"><B>Regulation FD Disclosure.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Attached hereto as Exhibit 99.1 is a copy
of the Company&rsquo;s press release, dated June 19, 2012, regarding the offering and sale of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The information furnished in this report
under this Item&nbsp;7.01, including Exhibit 99.1 attached hereto, shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 0; text-indent: 0; font-weight: bold"><B>Item 9.01 </B></TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; font-weight: bold"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"> (d) Exhibits. The following exhibits are filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: baseline">
    <TD STYLE="width: 12%; padding: 0; text-indent: 0; text-decoration: underline"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; text-decoration: underline"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">10.1</TD>
    <TD STYLE="padding: 0; text-indent: 0">Form of Subscription Agreement, dated as of June 18, 2012, between Medgenics, Inc. and the Subscriber named therein.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">10.2</TD>
    <TD STYLE="padding: 0; text-indent: 0">Form of Warrant Certificate, dated as of June 18, 2012.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">10.3</TD>
    <TD STYLE="padding: 0; text-indent: 0">Warrant Agreement, dated as of June 18, 2012, between Medgenics, Inc. and Corporate Stock Transfer, Inc., as warrant agent.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">10.4</TD>
    <TD STYLE="padding: 0; text-indent: 0">Common Stock Purchase Warrant, dated as of June 18, 2012, issued to Maxim Partners LLC.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">10.5</TD>
    <TD STYLE="padding: 0; text-indent: 0">Registration Rights Agreement, dated as of June 18, 2012, by and among Medgenics, Inc. and the investors party thereto.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding: 0; text-indent: 0">99.1</TD>
    <TD STYLE="padding: 0; text-indent: 0">Medgenics, Inc. Press Release dated June 19, 2012 (furnished pursuant to Item 7.01).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">MEDGENICS, INC.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="width: 30%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Phyllis K. Bellin</TD>
    <TD STYLE="width: 17%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name: Phyllis K. Bellin</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Title: Vice President &ndash; Administration</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&nbsp;&nbsp;&nbsp;June 19, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v316258_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 25476}]
{"company-data": {"conformed-name": "MEDGENICS, INC.", "cik": "0001138776", "assigned-sic": "2836", "irs-number": "980217544", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35112", "film-number": "12913901"}, "business-address": {"street1": "TERADION BUSINESS PK.", "street2": "P.O. BOX 14", "city": "MISGAV", "state": "L3", "zip": "20179", "phone": "1-646-239-1690"}, "mail-address": {"street1": "TERADION BUSINESS PK.", "street2": "P.O. BOX 14", "city": "MISGAV", "state": "L3", "zip": "20179"}, "former-company": {"former-conformed-name": "MEDGENICS INC", "date-changed": "20010419"}}
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 19, 2012 (June 18, 2012)
Date of Report (Date of earliest event reported)
MEDGENICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
1-35112
98-0217544
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
555 California Street, Suite 365
San Francisco, California 94104
(Address of principal executive offices,
zip code)
(415) 568-2245
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.
Entry into a Material Definitive Agreement.
Item 3.02.
Unregistered Sales of Equity Securities.
On June 18, 2012, Medgenics, Inc., a Delaware
corporation (the "Company"), entered into subscription agreements (the "Subscription Agreements") with
certain accredited investors (the "Investors") for the purchase and sale of an aggregate of 1,944,734 Units (the "Units"),
with each Unit consisting of one share of its common stock, par value $0.0001 per share, and a Warrant (collectively, the "Investor
Warrants") to purchase 0.75 share of its common stock, for an aggregate offering price of $9,529,196.60. The purchase price
per Unit was $4.90. The purchase and sale of the Units pursuant to the Subscription Agreements were completed on June 18, 2012
(the "Closing Date").
The
Units separated immediately upon closing, and the Investor Warrants were not separately listed for trading. The Investor Warrants
will first become exercisable on December 15, 2012, which is 180 days after the Closing Date, and will expire on June 18, 2017,
the fifth anniversary of the Closing Date. The Investor Warrants have an initial exercise price of $8.34 per full share of common
stock. The exercise price and number of shares issuable upon exercise of the Investor Warrants may be adjusted in certain circumstances,
including a stock split, stock dividend, recapitalization, reorganization, merger or consolidation, but will not be adjusted for
the issuance of common stock or securities convertible into or exercisable for common stock at a price below the then current exercise
price of the Investor Warrants. Holders of Investor Warrants will not have the right to exercise the Investor Warrants on a cashless
basis except during those periods, if any, that the Investor Warrants are exercisable and a registration statement with respect
to the resale of the common stock issuable upon exercise of the Investor Warrants is not effective. The terms of the Investor Warrants
are set forth in the Warrant Agreement, dated as of June 18, 2012, between the Company
and Corporate Stock Transfer, Inc.,
as warrant agent (the "Warrant Agreement").
The Company intends to use the net proceeds
from the sale of the Units for research and development, general corporate purposes and working capital needs.
Maxim Group LLC acted as placement agent
(the "Placement Agent") in connection with the offering, and received a commission equal to 8% and a corporate finance
fee equal to 2% of the gross proceeds raised in the offering, or $952,920 in the aggregate. Maxim Partners LLC, an affiliate of
the Placement Agent, was also issued a Common Stock Purchase Warrant dated as of June 18, 2012 (the "Placement Agent Warrant")
to purchase 194,473 shares of common stock (representing an amount equal to 10% of the shares sold as part of the Units) at an
initial exercise price of $9.17 per share (representing an exercise price equal to 110% of the exercise price of the Investor Warrants).
The Placement Agent Warrant will first become exercisable on December 18, 2012 and will expire on June 18, 2017. The exercise price
and number of shares issuable upon exercise of the Placement Agent Warrant may be adjusted in certain circumstances, including
a stock split, stock dividend, recapitalization, reorganization, merger or consolidation, but will not be adjusted for the issuance
of common stock or securities convertible into or exercisable for common stock at a price below the then current exercise price
of the Placement Agent Warrant. The Placement Agent Warrant may only be exercised on a cashless basis under the same terms and
conditions that the Investor Warrants may be exercised on a cashless basis.
In connection with the offer and sale of
the Units, the Company entered into a Registration Rights Agreement dated as of June 18, 2012 with the Investors (the "Registration
Rights Agreement"). Under the Registration Rights Agreement, the Company agreed to file a registration statement registering
the resale of the shares included in the Units and upon exercise of the Warrants within 30 days after the Closing Date. If the
registration statement is not filed within such 30-day period, or if the registration statement is not declared effective within
120 days after the Closing Date, the Company agreed to pay liquidated damages to the Investors equal to 1.0% of the aggregate purchase
price paid by each Investor per month. In no event will such liquidated damages exceed 5.0% of the aggregate purchase price paid
by the Investors. The Company is also obligated to register the resale of the shares issuable upon the exercise of the Placement
Agent Warrant under this registration statement.
The offering and sale of the Units has been
conducted in reliance upon an exemption from registration provided for by Rule 506 of Regulation D and Section 4(2) of the Securities
Act of 1933 (the "Act"). No form of general solicitation or general advertising was used by the Company, or any representative
of the Company, in connection with the offer or sale of the Units. Each of the Investors was an accredited investor. The shares
of common stock issued as part of the Units, the Investor Warrants, the Placement Agent Warrant, and the shares of common stock
issuable upon exercise of the Investor Warrants and the Placement Agent Warrant are restricted securities, have been or will be
appropriately legended as such, and cannot be transferred unless they have been registered under the Act, or there is an exemption
from registration under applicable federal and state securities laws.
The foregoing description of the Subscription
Agreements, Investor Warrants, Placement Agent Warrant and Registration Rights Agreement is only a summary and is qualified in
its entirety by reference to the full text of the form of Subscription Agreement, form of Warrant Certificate, Warrant Agreement,
Placement Agent Warrant and Registration Rights Agreement, each of which is filed as an exhibit hereto and incorporated herein
by reference.
Item 7.01
Regulation FD Disclosure.
Attached hereto as Exhibit 99.1 is a copy
of the Company's press release, dated June 19, 2012, regarding the offering and sale of the Units.
The information furnished in this report
under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith:
Exhibit No.
Description
10.1
Form of Subscription Agreement, dated as of June 18, 2012, between Medgenics, Inc. and the Subscriber named therein.
10.2
Form of Warrant Certificate, dated as of June 18, 2012.
10.3
Warrant Agreement, dated as of June 18, 2012, between Medgenics, Inc. and Corporate Stock Transfer, Inc., as warrant agent.
10.4
Common Stock Purchase Warrant, dated as of June 18, 2012, issued to Maxim Partners LLC.
10.5
Registration Rights Agreement, dated as of June 18, 2012, by and among Medgenics, Inc. and the investors party thereto.
99.1
Medgenics, Inc. Press Release dated June 19, 2012 (furnished pursuant to Item 7.01).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDGENICS, INC.
By:
/s/ Phyllis K. Bellin
Name: Phyllis K. Bellin
Title: Vice President – Administration
Date:   June 19, 2012